- Home
- JBTM vs ARWR Comparison
JBTM vs ARWR Comparison
Compare JBTM & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JBTM | ARWR |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 9.6B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | JBTM | ARWR |
|---|---|---|
| Price | $158.10 | $67.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $161.50 | $73.70 |
| AVG Volume (30 Days) | 463.0K | ★ 2.6M |
| Earning Date | 02-23-2026 | 02-05-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,257,800,000.00 | $829,448,000.00 |
| Revenue This Year | $124.13 | N/A |
| Revenue Next Year | $4.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 92.43 | ★ 23258.15 |
| 52 Week Low | $90.08 | $9.57 |
| 52 Week High | $160.84 | $76.76 |
Technical Indicators
Market Signals| Indicator | JBTM | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 58.82 | 57.08 |
| Support Level | $152.18 | $61.65 |
| Resistance Level | $160.40 | $68.24 |
| Average True Range (ATR) | 3.98 | 3.79 |
| MACD | -0.34 | -0.69 |
| Stochastic Oscillator | 77.52 | 45.29 |
Price Performance
Historical ComparisonAbout JBTM JBT Marel Corporation
JBT Marel Corp is a technology solutions provider to segments of the food and beverage industry. It designs, produces, and services products and systems for a broad range of end markets, generating roughly one-half of annual revenue from recurring parts, services, rebuilds, and leasing operations.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.